Efficacy and Safety Exposure–Response Analysis of Loncastuximab Tesirine in Patients with B cell non-Hodgkin Lymphoma-Reference-Cited by-同舟云学术

Efficacy and Safety Exposure–Response Analysis of Loncastuximab Tesirine in Patients with B cell non-Hodgkin Lymphoma

Published:2021-12-10 Issue:1 Volume:24 Page:
ISSN:1550-7416
Container-title:The AAPS Journal
language:en
Short-container-title:AAPS J

Author:

Hess Brian,Townsend William,Ai Weiyun,Stathis Anastasios,Solh Melhem,Alderuccio Juan Pablo,Ungar David,Liao Sam,Liao Lori,Khouri Lisa,Zhang Xiaoyan,Boni Joseph

Publisher

Springer Science and Business Media LLC

Subject

Pharmaceutical Science

Link

https://link.springer.com/content/pdf/10.1208/s12248-021-00660-3.pdf

Reference29 articles.

1. Sapkota S, Shaikh H. Non-Hodgkin lymphoma. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 [Updated 2020 Dec 14]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK559328/.

2. Al-Hamadani M, Habermann TM, Cerhan JR, Macon WR, Maurer MJ, Go RS. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the National Cancer Data Base from 1998 to 2011. Am J Hematol. 2015;90(9):790–5. https://doi.org/10.1002/ajh.24086.

3. Dreyling M, Ghielmini M, Rule S, Salles G, Vitolo U, Ladetto M. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(Suppl 5):v83–90. https://doi.org/10.1093/annonc/mdw400.

4. Dreyling M, Campo E, Hermine O, Jerkeman M, Le Gouill S, Rule S, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(Suppl 4):iv62–71. https://doi.org/10.1093/annonc/mdx223.

5. Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v116-25. https://doi.org/10.1093/annonc/mdv304.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Loncastuximab tesirine: Risk for dose variance;American Journal of Health-System Pharmacy;2024-01-31

2. Time‐dependent clearance can confound exposure–response analysis of therapeutic antibodies: A comprehensive review of the current literature;Clinical and Translational Science;2023-11-14

3. Harnessing the Immune System: An Effective Way to Manage Diffuse Large B-Cell Lymphoma;Journal of Hematology;2023-08

4. Safety of loncastuximab tesirine‐lpyl in diffuse large B‐cell lymphoma with severe hepatic dysfunction;Cancer;2023-05-19

5. Variable or variate? A conundrum in pharmacometrics exposure–response models;CPT: Pharmacometrics & Systems Pharmacology;2022-12-29